DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Woo | ko |
dc.contributor.author | Whang, Chang-Hee | ko |
dc.contributor.author | Kim, Dohyeon | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.date.accessioned | 2024-08-29T10:00:17Z | - |
dc.date.available | 2024-08-29T10:00:17Z | - |
dc.date.created | 2024-08-29 | - |
dc.date.issued | 2024-03 | - |
dc.identifier.citation | ADVANCED THERAPEUTICS, v.7, no.3 | - |
dc.identifier.issn | 2366-3987 | - |
dc.identifier.uri | http://hdl.handle.net/10203/322467 | - |
dc.description.abstract | Cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) play crucial roles in promoting tumor growth and facilitating immune evasion within the tumor microenvironment (TME)-functions that limit responses to immunotherapy. Recent research has highlighted the potential of celecoxib (CXB), a potent COX-2 selective inhibitor, for enhancing the effectiveness of immunotherapy by blocking the COX-2/PGE2 axis. However, the clinical application of CXB for cancer treatment is still hindered by its systemic adverse effects and lack of tumor-targeting. Here, to address these limitations, PEGylated prodrug CXB-derived nanoparticles (CXB-NPs) are developed, a nanomedicine designed to improve the tumor delivery of CXB while minimizing its adverse side effects. CXB-NPs demonstrate enhanced tumor accumulation and effectively inhibit tumor growth by improving the immunosuppressive TME in immunocompetent mice, surpassing the performance of parental CXB. Furthermore, when combined with anti-PD-1 antibody (alpha PD-1) immunotherapy, CXB-NPs exhibit superior suppression of CT26 tumor growth compared with alpha PD-1 monotherapy. This combination approach reduces the infiltration of immunosuppressive immune cells while promoting the infiltration and cytotoxicity of CD8+ T cells. The findings indicate that CXB-NPs capable of remodeling the TME provide a new combination therapy strategy for potentiating antitumor efficacy. Cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) play crucial roles in promoting tumor growth and facilitating immune evasion within the tumor microenvironment (TME). In this work, the development of PEGylated CXB-based nanoparticles (CXB-NPs) for enhanced tumor accumulation of CXB is reported, which effectively remodels the TME by inhibiting the COX-2/PGE2 axis. Together with aPD-1, CXB-NPs demonstrate synergistic antitumor efficacy against CT26 tumors.image | - |
dc.language | English | - |
dc.publisher | WILEY | - |
dc.title | Prodrug Celecoxib-Derived Nanoparticles Potentiate the Efficacy of Cancer Immunotherapy by Remodeling the Tumor Microenvironment | - |
dc.type | Article | - |
dc.identifier.wosid | 001146058500001 | - |
dc.identifier.scopusid | 2-s2.0-85182658267 | - |
dc.type.rims | ART | - |
dc.citation.volume | 7 | - |
dc.citation.issue | 3 | - |
dc.citation.publicationname | ADVANCED THERAPEUTICS | - |
dc.identifier.doi | 10.1002/adtp.202300321 | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.nonIdAuthor | Kim, Tae Woo | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | celecoxib | - |
dc.subject.keywordAuthor | COX-2 | - |
dc.subject.keywordAuthor | immunotherapy | - |
dc.subject.keywordAuthor | PEGylation | - |
dc.subject.keywordAuthor | tumor microenvironment | - |
dc.subject.keywordPlus | CELLS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.